346 related articles for article (PubMed ID: 36719091)
1. Ready-to-Use-Type Lyophilized Lipid Nanoparticle Formulation for the Postencapsulation of Messenger RNA.
Tanaka H; Hagiwara S; Shirane D; Yamakawa T; Sato Y; Matsumoto C; Ishizaki K; Hishinuma M; Chida K; Sasaki K; Yonemochi E; Ueda K; Higashi K; Moribe K; Tadokoro T; Maenaka K; Taneichi S; Nakai Y; Tange K; Sakurai Y; Akita H
ACS Nano; 2023 Feb; 17(3):2588-2601. PubMed ID: 36719091
[TBL] [Abstract][Full Text] [Related]
2. Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications.
Lopes C; Cristóvão J; Silvério V; Lino PR; Fonte P
Expert Opin Drug Deliv; 2022 Oct; 19(10):1381-1395. PubMed ID: 36223174
[TBL] [Abstract][Full Text] [Related]
3. Payload distribution and capacity of mRNA lipid nanoparticles.
Li S; Hu Y; Li A; Lin J; Hsieh K; Schneiderman Z; Zhang P; Zhu Y; Qiu C; Kokkoli E; Wang TH; Mao HQ
Nat Commun; 2022 Sep; 13(1):5561. PubMed ID: 36151112
[TBL] [Abstract][Full Text] [Related]
4. Chemistry of Lipid Nanoparticles for RNA Delivery.
Eygeris Y; Gupta M; Kim J; Sahay G
Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
[TBL] [Abstract][Full Text] [Related]
5. Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening.
Guimaraes PPG; Zhang R; Spektor R; Tan M; Chung A; Billingsley MM; El-Mayta R; Riley RS; Wang L; Wilson JM; Mitchell MJ
J Control Release; 2019 Dec; 316():404-417. PubMed ID: 31678653
[TBL] [Abstract][Full Text] [Related]
6. Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA.
Ball RL; Hajj KA; Vizelman J; Bajaj P; Whitehead KA
Nano Lett; 2018 Jun; 18(6):3814-3822. PubMed ID: 29694050
[TBL] [Abstract][Full Text] [Related]
7. Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA.
Miao H; Huang K; Li Y; Li R; Zhou X; Shi J; Tong Z; Sun Z; Yu A
Int J Pharm; 2023 Jun; 640():123050. PubMed ID: 37201764
[TBL] [Abstract][Full Text] [Related]
8. Encapsulating In Vitro Transcribed circRNA into Lipid Nanoparticles Via Microfluidic Mixing.
Juchem M; Cushman S; Lu D; Chatterjee S; Bär C; Thum T
Methods Mol Biol; 2024; 2765():247-260. PubMed ID: 38381344
[TBL] [Abstract][Full Text] [Related]
9. Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery.
Maeki M; Uno S; Niwa A; Okada Y; Tokeshi M
J Control Release; 2022 Apr; 344():80-96. PubMed ID: 35183654
[TBL] [Abstract][Full Text] [Related]
10. The mixing method used to formulate lipid nanoparticles affects mRNA delivery efficacy and organ tropism.
Strelkova Petersen DM; Chaudhary N; Arral ML; Weiss RM; Whitehead KA
Eur J Pharm Biopharm; 2023 Nov; 192():126-135. PubMed ID: 37838143
[TBL] [Abstract][Full Text] [Related]
11. Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing.
El-Mayta R; Padilla MS; Billingsley MM; Han X; Mitchell MJ
J Vis Exp; 2023 Jan; (191):. PubMed ID: 36744791
[TBL] [Abstract][Full Text] [Related]
12. Leveraging Biological Buffers for Efficient Messenger RNA Delivery via Lipid Nanoparticles.
Henderson MI; Eygeris Y; Jozic A; Herrera M; Sahay G
Mol Pharm; 2022 Nov; 19(11):4275-4285. PubMed ID: 36129254
[TBL] [Abstract][Full Text] [Related]
13. Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery.
Wang X; Liu S; Sun Y; Yu X; Lee SM; Cheng Q; Wei T; Gong J; Robinson J; Zhang D; Lian X; Basak P; Siegwart DJ
Nat Protoc; 2023 Jan; 18(1):265-291. PubMed ID: 36316378
[TBL] [Abstract][Full Text] [Related]
14. Development of a Microfluidic-Based Post-Treatment Process for Size-Controlled Lipid Nanoparticles and Application to siRNA Delivery.
Kimura N; Maeki M; Sato Y; Ishida A; Tani H; Harashima H; Tokeshi M
ACS Appl Mater Interfaces; 2020 Jul; 12(30):34011-34020. PubMed ID: 32667806
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic Studies of an Automated Lipid Nanoparticle Reveal Critical Pharmaceutical Properties Associated with Enhanced mRNA Functional Delivery In Vitro and In Vivo.
Cui L; Hunter MR; Sonzini S; Pereira S; Romanelli SM; Liu K; Li W; Liang L; Yang B; Mahmoudi N; Desai AS
Small; 2022 Mar; 18(9):e2105832. PubMed ID: 34914866
[TBL] [Abstract][Full Text] [Related]
16. Successful batch and continuous lyophilization of mRNA LNP formulations depend on cryoprotectants and ionizable lipids.
Lamoot A; Lammens J; De Lombaerde E; Zhong Z; Gontsarik M; Chen Y; De Beer TRM; De Geest BG
Biomater Sci; 2023 Jun; 11(12):4327-4334. PubMed ID: 37073472
[TBL] [Abstract][Full Text] [Related]
17. Investigations into mRNA Lipid Nanoparticles Shelf-Life Stability under Nonfrozen Conditions.
Reinhart AG; Osterwald A; Ringler P; Leiser Y; Lauer ME; Martin RE; Ullmer C; Schumacher F; Korn C; Keller M
Mol Pharm; 2023 Dec; 20(12):6492-6503. PubMed ID: 37975733
[TBL] [Abstract][Full Text] [Related]
18. Continuous freeze-drying of messenger RNA lipid nanoparticles enables storage at higher temperatures.
Meulewaeter S; Nuytten G; Cheng MHY; De Smedt SC; Cullis PR; De Beer T; Lentacker I; Verbeke R
J Control Release; 2023 May; 357():149-160. PubMed ID: 36958400
[TBL] [Abstract][Full Text] [Related]
19. Lipid nanoparticles containing labile PEG-lipids transfect primary human skin cells more efficiently in the presence of apoE.
Gregersen CH; Mearraoui R; Søgaard PP; Clergeaud G; Petersson K; Urquhart AJ; Simonsen JB
Eur J Pharm Biopharm; 2024 Apr; 197():114219. PubMed ID: 38368913
[TBL] [Abstract][Full Text] [Related]
20. Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing.
Qiu M; Li Y; Bloomer H; Xu Q
Acc Chem Res; 2021 Nov; 54(21):4001-4011. PubMed ID: 34668716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
